{"id":"https://openalex.org/W4393072736","doi":"https://doi.org/10.1158/1538-7445.am2024-595","title":"Abstract 595: Preclinical development of the CDK4 selective inhibitor PF-07220060: Increased CDK4 versus CDK6 inhibition leads to improved anti-tumor efficacy at therapeutic concentrations","display_name":"Abstract 595: Preclinical development of the CDK4 selective inhibitor PF-07220060: Increased CDK4 versus CDK6 inhibition leads to improved anti-tumor efficacy at therapeutic concentrations","publication_year":2024,"publication_date":"2024-03-22","ids":{"openalex":"https://openalex.org/W4393072736","doi":"https://doi.org/10.1158/1538-7445.am2024-595"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2024-595","doi":"https://doi.org/10.1158/1538-7445.am2024-595","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2024-595","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027847215","display_name":"Lars Anders","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lars Anders","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038316085","display_name":"Bernadette Pascual","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bernadette Pascual","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045824232","display_name":"Britton W. Boras","orcid":"https://orcid.org/0000-0003-3624-9177","observed_orcids":["https://orcid.org/0000-0003-3624-9177"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Britton Boras","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025157091","display_name":"Julie A. Cianfrogna","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie Cianfrogna","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077688228","display_name":"Scott J. Garza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott Garza","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Na Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Na Li","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004649875","display_name":"Jing Tang Yuan","orcid":"https://orcid.org/0000-0002-3844-5502","observed_orcids":["https://orcid.org/0000-0002-3844-5502"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing Tang Yuan","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028520737","display_name":"Mark A. Moen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Moen","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016891210","display_name":"Nanni H. Huser","orcid":"https://orcid.org/0009-0005-8709-0903","observed_orcids":["https://orcid.org/0009-0005-8709-0903"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nanni Huser","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059699253","display_name":"Gary M. Gallego","orcid":"https://orcid.org/0000-0002-5665-9416","observed_orcids":["https://orcid.org/0000-0002-5665-9416"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary Gallego","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056628506","display_name":"Mehran Jalaie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mehran Jalaie","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022936060","display_name":"Sacha Ninkovic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sacha Ninkovic","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069674726","display_name":"Sujin Cho-Schultz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sujin Cho-Schultz","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044435389","display_name":"Hong Shen","orcid":"https://orcid.org/0000-0002-1559-3633","observed_orcids":["https://orcid.org/0000-0002-1559-3633"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hong Shen","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027358753","display_name":"John C. Kath","orcid":"https://orcid.org/0009-0009-0685-4967","observed_orcids":["https://orcid.org/0009-0009-0685-4967"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Kath","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088511961","display_name":"Klaus R. Dress","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Klaus Dress","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088406785","display_name":"Wade C. Diehl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wade Diehl","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009572854","display_name":"Sajiv K. Nair","orcid":"https://orcid.org/0000-0002-8628-6999","observed_orcids":["https://orcid.org/0000-0002-8628-6999"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sajiv Nair","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079565808","display_name":"Rhys Jones","orcid":"https://orcid.org/0000-0002-5263-9194","observed_orcids":["https://orcid.org/0000-0002-5263-9194"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rhys Jones","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110715361","display_name":"Jennifer A. Lafontaine","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Lafontaine","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111598591","display_name":"Anwar Murtaza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anwar Murtaza","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037443663","display_name":"Aida I. Sacaan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aida Sacaan","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003229513","display_name":"Sudhakar R. Chintharlapalli","orcid":"https://orcid.org/0009-0000-2812-8557","observed_orcids":["https://orcid.org/0009-0000-2812-8557","https://orcid.org/0000-0001-7848-1674"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sudhakar Chintharlapalli","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060336842","display_name":"Todd L. VanArsdale","orcid":"https://orcid.org/0009-0003-7692-623X","observed_orcids":["https://orcid.org/0009-0003-7692-623X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Todd VanArsdale","raw_affiliation_strings":["1Pfizer Oncology, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Pfizer Oncology, San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"6_Supplement","first_page":"595","last_page":"595"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cdk4-inhibitors","display_name":"CDK4 inhibitors","score":0.8930000066757202},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.7080000042915344},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8640000224113464},{"id":"https://openalex.org/keywords/luminal-breast-cancer","display_name":"luminal breast cancer","score":0.8460000157356262},{"id":"https://openalex.org/keywords/androgen-receptor-positive-prostate-cancer","display_name":"androgen receptor-positive prostate cancer","score":0.7940000295639038},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.7710000276565552},{"id":"https://openalex.org/keywords/vepdegestrant","display_name":"vepdegestrant","score":0.9610000252723694},{"id":"https://openalex.org/keywords/enzalutamide","display_name":"enzalutamide","score":0.9760000109672546},{"id":"https://openalex.org/keywords/alpelisib","display_name":"alpelisib","score":0.9459999799728394},{"id":"https://openalex.org/keywords/cdk2-inhibition","display_name":"CDK2 inhibition","score":0.722000002861023},{"id":"https://openalex.org/keywords/senescence","display_name":"senescence","score":0.7820000052452087},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6949999928474426}],"concepts":[{"id":"https://openalex.org/C199649820","wikidata":"https://www.wikidata.org/wiki/Q14911762","display_name":"Cyclin-dependent kinase 6","level":5,"score":0.7917187213897705},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.6012511253356934},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5204061269760132},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5180537700653076},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3879072368144989},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.384014368057251},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3748459219932556},{"id":"https://openalex.org/C124320809","wikidata":"https://www.wikidata.org/wiki/Q46292","display_name":"Cyclin-dependent kinase","level":4,"score":0.3235982060432434},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.27415454387664795},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.16112780570983887},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.10212916135787964},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2024-595","doi":"https://doi.org/10.1158/1538-7445.am2024-595","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2024-595","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4393989020","https://openalex.org/W4402561342","https://openalex.org/W4379283321","https://openalex.org/W4402560121","https://openalex.org/W4399667236","https://openalex.org/W4397007018","https://openalex.org/W4408290569","https://openalex.org/W4409629071","https://openalex.org/W4417030207","https://openalex.org/W4399324371"],"abstract_inverted_index":{"Abstract":[0],"PF-07220060":[1,29,63,127,139,155,174,178,204],"is":[2,45,273,319],"a":[3,282],"selective":[4,384],"inhibitor":[5,225,385],"of":[6,56,62,81,222,237,249,262,284,381,403],"CDK4,":[7],"displaying":[8],"~20-fold":[9],"and":[10,22,35,51,75,106,114,150,167,172,205,289],"~4-fold":[11],"increased":[12,200],"selectivity":[13],"for":[14,266,407],"CDK4":[15,83,102,238,267,383,388],"versus":[16,207,389],"CDK6":[17,105,263,277,390],"when":[18,37,304],"compared":[19,38],"to":[20,27,39,68,131,145,182,229,243,264,302,322,393],"palbociclib":[21],"abemaciclib/ribociclib,":[23],"respectively.":[24],"This":[25],"translates":[26],"less":[28],"associated":[30],"neutropenia":[31,44],"in":[32,65,73,85,135,233,246,269,280,287,290,295],"beagle":[33],"dogs":[34],"humans":[36],"dual":[40,57,325],"CDK4/6":[41,58,326],"inhibitors.":[42,327],"Because":[43],"the":[46,60,66,70,82,146,151,183,194,212,223,260,285,382,404],"primary":[47],"culprit":[48],"necessitating":[49],"limited":[50],"often":[52],"interrupted":[53],"clinical":[54],"dosing":[55],"inhibitors,":[59],"advantage":[61],"lies":[64],"flexibility":[67],"escalate":[69],"drug\u2019s":[71],"exposure":[72],"patients":[74],"thus":[76],"realize":[77],"near-complete":[78],"target":[79],"coverage":[80],"oncogene":[84],"tumors":[86],"that":[87,98,259,315],"are":[88],"dependent":[89],"on":[90,101],"this":[91],"kinase.":[92],"Here":[93],"we":[94,121],"select":[95],"tumor":[96,137,161,217,231,244,271],"types/indications":[97],"show":[99],"dependency":[100],"but":[103],"not":[104,215],"includes":[107],"cells":[108],"derived":[109],"from":[110],"luminal":[111],"breast":[112,143,191,252],"cancer":[113,144,181,192],"androgen-receptor":[115],"positive":[116],"metastatic":[117],"prostate":[118,180],"cancer.":[119,253],"Additionally,":[120],"investigate":[122],"certain":[123],"drugs":[124,306],"with":[125,203],"which":[126],"may":[128],"be":[129],"combined":[130],"maximize":[132],"its":[133],"efficacy":[134,299,318,396],"these":[136,270,296],"indications.":[138],"sensitizes":[140,179],"HR+":[141,189],"HER2-":[142,190,251],"estrogen":[147],"inhibitor,":[148],"fulvestrant":[149,206],"degrader,":[152],"ARV-471":[153],"(vepdegestrant).":[154],"+":[156,170,175],"vepdegestrant":[157,171],"showed":[158],"significantly":[159],"longer":[160],"regrowth":[162],"delay":[163],"vs":[164,168,173],"monotherapy":[165],"groups":[166],"Palbo":[169],"fulvestrant*.":[176],"Similarly,":[177],"androgen":[184],"receptor":[185],"antagonist,":[186],"enzalutamide.":[187],"In":[188],"cells,":[193],"senescent":[195],"cell":[196,218],"fraction":[197,283],"was":[198,227,278],"markedly":[199],"by":[201,276],"co-treatment":[202],"either":[208],"drug":[209],"alone,":[210],"albeit":[211],"combination":[213],"did":[214],"trigger":[216],"death.":[219],"Further":[220],"addition":[221],"PI3K":[224],"alpelisib":[226],"sufficient":[228],"enforce":[230],"shrinkage":[232,245],"vivo.":[234],"Alternatively,":[235],"inhibition":[236,268,391],"plus":[239],"CDK2":[240],"also":[241],"led":[242],"xenograft":[247],"models":[248],"HR+,":[250],"Finally,":[254],"our":[255],"preclinical":[256],"data":[257],"indicate":[258],"propensity":[261],"compensate":[265],"types":[272],"limited.":[274],"Compensation":[275],"seen":[279],"only":[281],"evaluated":[286],"vitro":[288],"vivo":[291],"models.":[292],"Even":[293],"so,":[294],"instances,":[297],"PF-07220060\u2019s":[298,316],"remained":[300],"comparable":[301],"palbociclib\u2019s":[303],"both":[305],"were":[307],"used":[308],"at":[309,397],"their":[310],"therapeutic":[311,398],"doses.":[312],"We":[313],"conclude":[314],"anti-tumor":[317,395],"broadly":[320],"superior":[321],"currently":[323],"approved":[324],"Citation":[328],"Format:":[329],"Lars":[330],"Anders,":[331],"Bernadette":[332],"Pascual,":[333],"Britton":[334],"Boras,":[335],"Julie":[336],"Cianfrogna,":[337],"Scott":[338],"Garza,":[339],"Na":[340],"Li,":[341],"Jing":[342],"Tang":[343],"Yuan,":[344],"Mark":[345],"Moen,":[346],"Nanni":[347],"Huser,":[348],"Gary":[349],"Gallego,":[350],"Mehran":[351],"Jalaie,":[352],"Sacha":[353],"Ninkovic,":[354],"Sujin":[355],"Cho-Schultz,":[356],"Hong":[357],"Shen,":[358],"John":[359],"Kath,":[360],"Klaus":[361],"Dress,":[362],"Wade":[363],"Diehl,":[364],"Sajiv":[365],"Nair,":[366],"Rhys":[367],"Jones,":[368],"Jennifer":[369],"Lafontaine,":[370],"Anwar":[371],"Murtaza,":[372],"Aida":[373],"Sacaan,":[374],"Sudhakar":[375],"Chintharlapalli,":[376],"Todd":[377],"VanArsdale.":[378],"Preclinical":[379],"development":[380],"PF-07220060:":[386],"Increased":[387],"leads":[392],"improved":[394],"concentrations":[399],"[abstract].":[400],"In:":[401],"Proceedings":[402],"American":[405],"Association":[406],"Cancer":[408,426],"Research":[409],"Annual":[410],"Meeting":[411],"2024;":[412],"Part":[413],"1":[414],"(Regular":[415],"Abstracts);":[416],"2024":[417],"Apr":[418],"5-10;":[419],"San":[420],"Diego,":[421],"CA.":[422],"Philadelphia":[423],"(PA):":[424],"AACR;":[425],"Res":[427],"2024;84(6_Suppl):Abstract":[428],"nr":[429],"595.":[430]},"counts_by_year":[{"year":2025,"cited_by_count":3}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2024-03-23T00:00:00"}